A Prostate Cancer “Nimbosus”: Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies
Intraductal carcinoma (IDC) and cribriform architecture (CA) represent unfavorable subpathologies in localized prostate cancer. We recently showed that IDC shares a clonal ancestry with the adjacent glandular adenocarcinoma. We investigated for the co-occurrence of “aggression” factors, genomic inst...
Saved in:
| Published in | European urology Vol. 72; no. 5; pp. 665 - 674 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
Elsevier B.V
01.11.2017
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0302-2838 1873-7560 1873-7560 |
| DOI | 10.1016/j.eururo.2017.04.034 |
Cover
| Abstract | Intraductal carcinoma (IDC) and cribriform architecture (CA) represent unfavorable subpathologies in localized prostate cancer. We recently showed that IDC shares a clonal ancestry with the adjacent glandular adenocarcinoma.
We investigated for the co-occurrence of “aggression” factors, genomic instability and hypoxia, and performed gene expression profiling of these tumors.
A total of 1325 men were treated for localized prostate cancer from four academic institutions (University Health Network, CHU de Québec-Université Laval, Memorial Sloan Kettering Cancer Center [MSKCC], and Erasmus Medical Center). Pathological specimens were centrally reviewed. Gene copy number and expression, and intraprostatic oxygenation were assessed.
IDC/CA was separately assessed for biochemical relapse risk in the Canadian and MSKCC cohorts. Both cohorts were pooled for analyses on metastasis.
Presence of IDC/CA independently predicted for increased risks of biochemical relapse (HRCanadian 2.17, p<0.001; HRMSKCC 2.32, p=0.0035) and metastasis (HRpooled 3.31, p<0.001). IDC/CA+ cancers were associated with an increased percentage of genome alteration (PGA [median] 7.2 vs 3.0, p<0.001), and hypoxia (64.0% vs 45.5%, p=0.17). Combinatorial genomic–pathological indices offered the strongest discrimination for metastasis (C-index 0.805 [clinical+IDC/CA+PGA] vs 0.786 [clinical+IDC/CA] vs 0.761 [clinical]). Profiling of mRNA abundance revealed that long noncoding RNA, SChLAP1, was the only gene expressed at >3-fold higher (p<0.0001) in IDC/CA+ than in IDC/CA– tumors, independently corroborated by increased SChLAP1 RNA in situ hybridization signal. Optimal treatment intensification for IDC/CA+ prostate cancer requires prospective testing.
The poor outcome associated with IDC and CA subpathologies is associated with a constellation of genomic instability, SChLAP1 expression, and hypoxia. We posit a novel concept in IDC/CA+ prostate cancer, “nimbosus” (gathering of stormy clouds, Latin), which manifests as increased metastatic capacity and lethality.
A constellation of unfavorable molecular characteristics co-occur with intraductal and cribriform subpathologies in prostate cancer. Modern imaging for surveillance and treatment intensification trials should be considered in this adverse subgroup.
We posit a prostate cancer “nimbosus” that is hallmarked by the constellation of genomic instability, SChLAP1 dysregulation, hypoxia, and intraductal-cribriform subpathologies. Patients harboring these prostate cancers should be closely monitored and are recommended intensified treatment against an increased risk of metastases. |
|---|---|
| AbstractList | Intraductal carcinoma (IDC) and cribriform architecture (CA) represent unfavorable subpathologies in localized prostate cancer. We recently showed that IDC shares a clonal ancestry with the adjacent glandular adenocarcinoma.
We investigated for the co-occurrence of “aggression” factors, genomic instability and hypoxia, and performed gene expression profiling of these tumors.
A total of 1325 men were treated for localized prostate cancer from four academic institutions (University Health Network, CHU de Québec-Université Laval, Memorial Sloan Kettering Cancer Center [MSKCC], and Erasmus Medical Center). Pathological specimens were centrally reviewed. Gene copy number and expression, and intraprostatic oxygenation were assessed.
IDC/CA was separately assessed for biochemical relapse risk in the Canadian and MSKCC cohorts. Both cohorts were pooled for analyses on metastasis.
Presence of IDC/CA independently predicted for increased risks of biochemical relapse (HRCanadian 2.17, p<0.001; HRMSKCC 2.32, p=0.0035) and metastasis (HRpooled 3.31, p<0.001). IDC/CA+ cancers were associated with an increased percentage of genome alteration (PGA [median] 7.2 vs 3.0, p<0.001), and hypoxia (64.0% vs 45.5%, p=0.17). Combinatorial genomic–pathological indices offered the strongest discrimination for metastasis (C-index 0.805 [clinical+IDC/CA+PGA] vs 0.786 [clinical+IDC/CA] vs 0.761 [clinical]). Profiling of mRNA abundance revealed that long noncoding RNA, SChLAP1, was the only gene expressed at >3-fold higher (p<0.0001) in IDC/CA+ than in IDC/CA– tumors, independently corroborated by increased SChLAP1 RNA in situ hybridization signal. Optimal treatment intensification for IDC/CA+ prostate cancer requires prospective testing.
The poor outcome associated with IDC and CA subpathologies is associated with a constellation of genomic instability, SChLAP1 expression, and hypoxia. We posit a novel concept in IDC/CA+ prostate cancer, “nimbosus” (gathering of stormy clouds, Latin), which manifests as increased metastatic capacity and lethality.
A constellation of unfavorable molecular characteristics co-occur with intraductal and cribriform subpathologies in prostate cancer. Modern imaging for surveillance and treatment intensification trials should be considered in this adverse subgroup.
We posit a prostate cancer “nimbosus” that is hallmarked by the constellation of genomic instability, SChLAP1 dysregulation, hypoxia, and intraductal-cribriform subpathologies. Patients harboring these prostate cancers should be closely monitored and are recommended intensified treatment against an increased risk of metastases. Intraductal carcinoma (IDC) and cribriform architecture (CA) represent unfavorable subpathologies in localized prostate cancer. We recently showed that IDC shares a clonal ancestry with the adjacent glandular adenocarcinoma.BACKGROUNDIntraductal carcinoma (IDC) and cribriform architecture (CA) represent unfavorable subpathologies in localized prostate cancer. We recently showed that IDC shares a clonal ancestry with the adjacent glandular adenocarcinoma.We investigated for the co-occurrence of "aggression" factors, genomic instability and hypoxia, and performed gene expression profiling of these tumors.OBJECTIVEWe investigated for the co-occurrence of "aggression" factors, genomic instability and hypoxia, and performed gene expression profiling of these tumors.A total of 1325 men were treated for localized prostate cancer from four academic institutions (University Health Network, CHU de Québec-Université Laval, Memorial Sloan Kettering Cancer Center [MSKCC], and Erasmus Medical Center). Pathological specimens were centrally reviewed. Gene copy number and expression, and intraprostatic oxygenation were assessed.DESIGN, SETTING, AND PARTICIPANTSA total of 1325 men were treated for localized prostate cancer from four academic institutions (University Health Network, CHU de Québec-Université Laval, Memorial Sloan Kettering Cancer Center [MSKCC], and Erasmus Medical Center). Pathological specimens were centrally reviewed. Gene copy number and expression, and intraprostatic oxygenation were assessed.IDC/CA was separately assessed for biochemical relapse risk in the Canadian and MSKCC cohorts. Both cohorts were pooled for analyses on metastasis.OUTCOME MEASUREMENTS AND STATISTICAL ANALYSISIDC/CA was separately assessed for biochemical relapse risk in the Canadian and MSKCC cohorts. Both cohorts were pooled for analyses on metastasis.Presence of IDC/CA independently predicted for increased risks of biochemical relapse (HRCanadian 2.17, p<0.001; HRMSKCC 2.32, p=0.0035) and metastasis (HRpooled 3.31, p<0.001). IDC/CA+ cancers were associated with an increased percentage of genome alteration (PGA [median] 7.2 vs 3.0, p<0.001), and hypoxia (64.0% vs 45.5%, p=0.17). Combinatorial genomic-pathological indices offered the strongest discrimination for metastasis (C-index 0.805 [clinical+IDC/CA+PGA] vs 0.786 [clinical+IDC/CA] vs 0.761 [clinical]). Profiling of mRNA abundance revealed that long noncoding RNA, SChLAP1, was the only gene expressed at >3-fold higher (p<0.0001) in IDC/CA+ than in IDC/CA- tumors, independently corroborated by increased SChLAP1 RNA in situ hybridization signal. Optimal treatment intensification for IDC/CA+ prostate cancer requires prospective testing.RESULTS AND LIMITATIONPresence of IDC/CA independently predicted for increased risks of biochemical relapse (HRCanadian 2.17, p<0.001; HRMSKCC 2.32, p=0.0035) and metastasis (HRpooled 3.31, p<0.001). IDC/CA+ cancers were associated with an increased percentage of genome alteration (PGA [median] 7.2 vs 3.0, p<0.001), and hypoxia (64.0% vs 45.5%, p=0.17). Combinatorial genomic-pathological indices offered the strongest discrimination for metastasis (C-index 0.805 [clinical+IDC/CA+PGA] vs 0.786 [clinical+IDC/CA] vs 0.761 [clinical]). Profiling of mRNA abundance revealed that long noncoding RNA, SChLAP1, was the only gene expressed at >3-fold higher (p<0.0001) in IDC/CA+ than in IDC/CA- tumors, independently corroborated by increased SChLAP1 RNA in situ hybridization signal. Optimal treatment intensification for IDC/CA+ prostate cancer requires prospective testing.The poor outcome associated with IDC and CA subpathologies is associated with a constellation of genomic instability, SChLAP1 expression, and hypoxia. We posit a novel concept in IDC/CA+ prostate cancer, "nimbosus" (gathering of stormy clouds, Latin), which manifests as increased metastatic capacity and lethality.CONCLUSIONSThe poor outcome associated with IDC and CA subpathologies is associated with a constellation of genomic instability, SChLAP1 expression, and hypoxia. We posit a novel concept in IDC/CA+ prostate cancer, "nimbosus" (gathering of stormy clouds, Latin), which manifests as increased metastatic capacity and lethality.A constellation of unfavorable molecular characteristics co-occur with intraductal and cribriform subpathologies in prostate cancer. Modern imaging for surveillance and treatment intensification trials should be considered in this adverse subgroup.PATIENT SUMMARYA constellation of unfavorable molecular characteristics co-occur with intraductal and cribriform subpathologies in prostate cancer. Modern imaging for surveillance and treatment intensification trials should be considered in this adverse subgroup. Abstract Background Intraductal carcinoma (IDC) and cribriform architecture (CA) represent unfavorable subpathologies in localized prostate cancer. We recently showed that IDC shares a clonal ancestry with the adjacent glandular adenocarcinoma. Objective We investigated for the co-occurrence of “aggression” factors, genomic instability and hypoxia, and performed gene expression profiling of these tumors. Design, setting, and participants A total of 1325 men were treated for localized prostate cancer from four academic institutions (University Health Network, CHU de Québec-Université Laval, Memorial Sloan Kettering Cancer Center [MSKCC], and Erasmus Medical Center). Pathological specimens were centrally reviewed. Gene copy number and expression, and intraprostatic oxygenation were assessed. Outcome measurements and statistical analysis IDC/CA was separately assessed for biochemical relapse risk in the Canadian and MSKCC cohorts. Both cohorts were pooled for analyses on metastasis. Results and limitation Presence of IDC/CA independently predicted for increased risks of biochemical relapse (HRCanadian 2.17, p < 0.001; HRMSKCC 2.32, p = 0.0035) and metastasis (HRpooled 3.31, p < 0.001). IDC/CA+ cancers were associated with an increased percentage of genome alteration (PGA [median] 7.2 vs 3.0, p < 0.001), and hypoxia (64.0% vs 45.5%, p = 0.17). Combinatorial genomic–pathological indices offered the strongest discrimination for metastasis (C-index 0.805 [clinical + IDC/CA + PGA] vs 0.786 [clinical + IDC/CA] vs 0.761 [clinical]). Profiling of mRNA abundance revealed that long noncoding RNA, SChLAP1 , was the only gene expressed at >3-fold higher ( p < 0.0001) in IDC/CA+ than in IDC/CA– tumors, independently corroborated by increased SChLAP1 RNA in situ hybridization signal. Optimal treatment intensification for IDC/CA+ prostate cancer requires prospective testing. Conclusions The poor outcome associated with IDC and CA subpathologies is associated with a constellation of genomic instability, SChLAP1 expression, and hypoxia. We posit a novel concept in IDC/CA+ prostate cancer, “ nimbosus ” (gathering of stormy clouds, Latin), which manifests as increased metastatic capacity and lethality. Patient summary A constellation of unfavorable molecular characteristics co-occur with intraductal and cribriform subpathologies in prostate cancer. Modern imaging for surveillance and treatment intensification trials should be considered in this adverse subgroup. Intraductal carcinoma (IDC) and cribriform architecture (CA) represent unfavorable subpathologies in localized prostate cancer. We recently showed that IDC shares a clonal ancestry with the adjacent glandular adenocarcinoma. We investigated for the co-occurrence of "aggression" factors, genomic instability and hypoxia, and performed gene expression profiling of these tumors. A total of 1325 men were treated for localized prostate cancer from four academic institutions (University Health Network, CHU de Québec-Université Laval, Memorial Sloan Kettering Cancer Center [MSKCC], and Erasmus Medical Center). Pathological specimens were centrally reviewed. Gene copy number and expression, and intraprostatic oxygenation were assessed. IDC/CA was separately assessed for biochemical relapse risk in the Canadian and MSKCC cohorts. Both cohorts were pooled for analyses on metastasis. Presence of IDC/CA independently predicted for increased risks of biochemical relapse (HR 2.17, p<0.001; HR 2.32, p=0.0035) and metastasis (HR 3.31, p<0.001). IDC/CA+ cancers were associated with an increased percentage of genome alteration (PGA [median] 7.2 vs 3.0, p<0.001), and hypoxia (64.0% vs 45.5%, p=0.17). Combinatorial genomic-pathological indices offered the strongest discrimination for metastasis (C-index 0.805 [clinical+IDC/CA+PGA] vs 0.786 [clinical+IDC/CA] vs 0.761 [clinical]). Profiling of mRNA abundance revealed that long noncoding RNA, SChLAP1, was the only gene expressed at >3-fold higher (p<0.0001) in IDC/CA+ than in IDC/CA- tumors, independently corroborated by increased SChLAP1 RNA in situ hybridization signal. Optimal treatment intensification for IDC/CA+ prostate cancer requires prospective testing. The poor outcome associated with IDC and CA subpathologies is associated with a constellation of genomic instability, SChLAP1 expression, and hypoxia. We posit a novel concept in IDC/CA+ prostate cancer, "nimbosus" (gathering of stormy clouds, Latin), which manifests as increased metastatic capacity and lethality. A constellation of unfavorable molecular characteristics co-occur with intraductal and cribriform subpathologies in prostate cancer. Modern imaging for surveillance and treatment intensification trials should be considered in this adverse subgroup. |
| Author | Lo, Winnie Lacombe, Louis Têtu, Bernard Zhang, Junyan Bristow, Robert G. Reuter, Victor E. Boutros, Paul C. Lalonde, Emilie Kweldam, Charlotte F. Hoogland, Agnes Marije Hovington, Hélène Bhandari, Vinayak Dal Pra, Alan Orain, Michèle Gopalan, Anuradha Berlin, Alejandro van der Kwast, Theodorus H. Chua, Melvin L.K. Meng, Alice Fleshner, Neil Pintilie, Melania Verhoef, Esther I. Fraser, Michael van Leenders, Geert J.L.H. Bergeron, Alain Murgic, Jure Mahamud, Osman Livingstone, Julie Picard, Valérie Fradet, Yves |
| Author_xml | – sequence: 1 givenname: Melvin L.K. orcidid: 0000-0002-1648-1473 surname: Chua fullname: Chua, Melvin L.K. organization: Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada – sequence: 2 givenname: Winnie surname: Lo fullname: Lo, Winnie organization: Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada – sequence: 3 givenname: Melania surname: Pintilie fullname: Pintilie, Melania organization: Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada – sequence: 4 givenname: Jure surname: Murgic fullname: Murgic, Jure organization: Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada – sequence: 5 givenname: Emilie surname: Lalonde fullname: Lalonde, Emilie organization: Informatics and Biocomputing Program, Ontario Institute for Cancer Research, Toronto, ON, Canada – sequence: 6 givenname: Vinayak surname: Bhandari fullname: Bhandari, Vinayak organization: Informatics and Biocomputing Program, Ontario Institute for Cancer Research, Toronto, ON, Canada – sequence: 7 givenname: Osman surname: Mahamud fullname: Mahamud, Osman organization: Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada – sequence: 8 givenname: Anuradha surname: Gopalan fullname: Gopalan, Anuradha organization: Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA – sequence: 9 givenname: Charlotte F. surname: Kweldam fullname: Kweldam, Charlotte F. organization: Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands – sequence: 10 givenname: Geert J.L.H. surname: van Leenders fullname: van Leenders, Geert J.L.H. organization: Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands – sequence: 11 givenname: Esther I. surname: Verhoef fullname: Verhoef, Esther I. organization: Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands – sequence: 12 givenname: Agnes Marije surname: Hoogland fullname: Hoogland, Agnes Marije organization: Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands – sequence: 13 givenname: Julie surname: Livingstone fullname: Livingstone, Julie organization: Informatics and Biocomputing Program, Ontario Institute for Cancer Research, Toronto, ON, Canada – sequence: 14 givenname: Alejandro surname: Berlin fullname: Berlin, Alejandro organization: Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada – sequence: 15 givenname: Alan surname: Dal Pra fullname: Dal Pra, Alan organization: Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada – sequence: 16 givenname: Alice surname: Meng fullname: Meng, Alice organization: Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada – sequence: 17 givenname: Junyan surname: Zhang fullname: Zhang, Junyan organization: Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada – sequence: 18 givenname: Michèle surname: Orain fullname: Orain, Michèle organization: Centre de Recherche du CHU de Québec-Université Laval, Québec City, QC, Canada – sequence: 19 givenname: Valérie surname: Picard fullname: Picard, Valérie organization: Centre de Recherche du CHU de Québec-Université Laval, Québec City, QC, Canada – sequence: 20 givenname: Hélène surname: Hovington fullname: Hovington, Hélène organization: Centre de Recherche du CHU de Québec-Université Laval, Québec City, QC, Canada – sequence: 21 givenname: Alain surname: Bergeron fullname: Bergeron, Alain organization: Centre de Recherche du CHU de Québec-Université Laval, Québec City, QC, Canada – sequence: 22 givenname: Louis surname: Lacombe fullname: Lacombe, Louis organization: Centre de Recherche du CHU de Québec-Université Laval, Québec City, QC, Canada – sequence: 23 givenname: Yves surname: Fradet fullname: Fradet, Yves organization: Centre de Recherche du CHU de Québec-Université Laval, Québec City, QC, Canada – sequence: 24 givenname: Bernard surname: Têtu fullname: Têtu, Bernard organization: Centre de Recherche du CHU de Québec-Université Laval, Québec City, QC, Canada – sequence: 25 givenname: Victor E. surname: Reuter fullname: Reuter, Victor E. organization: Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA – sequence: 26 givenname: Neil surname: Fleshner fullname: Fleshner, Neil organization: Division of Urology, University Health Network, University of Toronto, Toronto, ON, Canada – sequence: 27 givenname: Michael surname: Fraser fullname: Fraser, Michael organization: Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada – sequence: 28 givenname: Paul C. surname: Boutros fullname: Boutros, Paul C. organization: Informatics and Biocomputing Program, Ontario Institute for Cancer Research, Toronto, ON, Canada – sequence: 29 givenname: Theodorus H. surname: van der Kwast fullname: van der Kwast, Theodorus H. email: Theodorus.vanderKwast@uhn.ca organization: Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands – sequence: 30 givenname: Robert G. surname: Bristow fullname: Bristow, Robert G. email: Rob.Bristow@rmp.uhn.on.ca organization: Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28511883$$D View this record in MEDLINE/PubMed |
| BookMark | eNqVktFqFDEYhYNU7Hb1DURy6c2uySSzkykiLKPWwqKFtdchk_lnm3UmWZOMsHd9hD5Afbk-iZlu9UKQIiEEwvlOyDn_CTqyzgJCLymZU0IXb7ZzGPzg3TwjtJgTPieMP0ETKgo2K_IFOUITwkg2ywQTx-gkhC0hhOUle4aOM5FTKgSboJslvvAuRBUBV8pq8Pju-vaz6WsXhnB3_fMUn4F1vdH43CZZbToT91jZBq-rq9XyguL3--BhM3QqGmfxpW3A74zFy83GQwjjnWsTHL1qBh1Vdw9X3tTetM73eD3UOxWvXOc2BsJz9LRVXYAXD-cUXX788LX6NFt9OTuvlquZztkizlTDS5o24U2WfpUWX3BaAteizDTUraiFaluSMxA0q3NQqmW8ZjXwkjUZZ1P0-uC78-77ACHK3gQNXacsuCFIKsqyKJlIcU7RqwfpUPfQyJ03vfJ7-TvFJOAHgU5RpjDaPxJK5FiW3MpDWXIsSxIuU1kJO_0L0ybep5iyMt1j8LsDDCmkHwa8DNpAKrAxHnSUjTP_a6A7Y41W3TfYQ9i6wdtUgKQyZJLI9ThM4yzRgiWc58ng7b8NHn__F4up370 |
| CitedBy_id | crossref_primary_10_1038_s41585_019_0195_1 crossref_primary_10_1016_j_juro_2017_07_037 crossref_primary_10_1038_s41568_024_00781_9 crossref_primary_10_1111_his_14945 crossref_primary_10_1016_j_neo_2024_101023 crossref_primary_10_1007_s00428_019_02544_6 crossref_primary_10_1080_14737140_2018_1469406 crossref_primary_10_1038_s41379_019_0221_0 crossref_primary_10_1016_j_euo_2018_03_013 crossref_primary_10_1016_j_pathol_2023_05_004 crossref_primary_10_1016_j_urolonc_2020_08_027 crossref_primary_10_1111_his_14711 crossref_primary_10_1038_s41391_024_00910_3 crossref_primary_10_1016_j_path_2018_07_001 crossref_primary_10_3390_cancers14133041 crossref_primary_10_1073_pnas_1918744117 crossref_primary_10_1016_j_juro_2018_01_081 crossref_primary_10_1111_bju_14812 crossref_primary_10_1200_PO_20_00016 crossref_primary_10_1016_j_clon_2019_11_002 crossref_primary_10_1016_j_trecan_2020_05_011 crossref_primary_10_52547_rbmb_10_1_60 crossref_primary_10_1126_scitranslmed_aaz0152 crossref_primary_10_1016_j_euo_2023_06_007 crossref_primary_10_1016_j_eururo_2023_03_014 crossref_primary_10_1111_his_13747 crossref_primary_10_3389_fonc_2022_876531 crossref_primary_10_1038_s41379_022_01093_9 crossref_primary_10_17352_2581_5407_000033 crossref_primary_10_3389_fruro_2024_1487873 crossref_primary_10_1016_j_euo_2018_08_003 crossref_primary_10_1016_j_path_2021_05_004 crossref_primary_10_1259_bjr_20200087 crossref_primary_10_1016_j_euo_2023_12_006 crossref_primary_10_1016_j_eururo_2021_06_002 crossref_primary_10_1016_j_humpath_2020_02_004 crossref_primary_10_1038_s41467_022_33780_1 crossref_primary_10_1016_j_eururo_2017_11_029 crossref_primary_10_1038_s41467_018_08133_6 crossref_primary_10_1177_0391560319876821 crossref_primary_10_1016_j_prp_2018_03_003 crossref_primary_10_1016_j_tig_2019_08_004 crossref_primary_10_1038_s41391_024_00802_6 crossref_primary_10_3390_ijms222313125 crossref_primary_10_1080_14737159_2019_1665998 crossref_primary_10_1186_s13045_022_01268_6 crossref_primary_10_1016_j_neo_2021_05_012 crossref_primary_10_1016_j_canlet_2021_05_014 crossref_primary_10_1002_cjp2_205 crossref_primary_10_1002_pros_24809 crossref_primary_10_1158_1541_7786_MCR_18_0440 crossref_primary_10_3389_fonc_2017_00305 crossref_primary_10_3390_medicines6030082 crossref_primary_10_1016_j_clgc_2022_01_003 crossref_primary_10_1016_j_clgc_2023_03_010 crossref_primary_10_1016_j_eururo_2019_07_051 crossref_primary_10_1016_j_cell_2019_01_025 crossref_primary_10_1177_17562872221125317 crossref_primary_10_1016_j_neo_2024_100983 crossref_primary_10_1111_his_14214 crossref_primary_10_1002_pros_24492 crossref_primary_10_1002_pros_23942 crossref_primary_10_1016_j_modpat_2023_100130 crossref_primary_10_1016_j_path_2022_07_001 crossref_primary_10_1080_14737159_2021_1996227 crossref_primary_10_3390_cancers15051372 crossref_primary_10_1002_cam4_6939 crossref_primary_10_1016_j_ejca_2021_01_027 crossref_primary_10_1016_j_eururo_2020_05_009 crossref_primary_10_1097_PAS_0000000000001417 crossref_primary_10_1111_his_13767 crossref_primary_10_1038_s41585_018_0013_1 crossref_primary_10_1097_PAP_0000000000000444 crossref_primary_10_1016_j_urolonc_2021_08_013 crossref_primary_10_1097_PAP_0000000000000168 crossref_primary_10_1016_j_path_2024_10_001 crossref_primary_10_1038_s41585_019_0164_8 crossref_primary_10_1016_j_eururo_2017_05_015 crossref_primary_10_1038_s41585_021_00500_1 crossref_primary_10_1002_pros_23831 crossref_primary_10_1021_acs_analchem_7b03536 crossref_primary_10_1111_his_14064 crossref_primary_10_1186_s12885_024_12505_1 crossref_primary_10_1016_j_ijrobp_2018_08_030 crossref_primary_10_1016_j_eururo_2022_07_002 crossref_primary_10_1097_MOU_0000000000000669 crossref_primary_10_1111_his_14901 crossref_primary_10_1111_bju_15530 crossref_primary_10_1111_bju_14043 crossref_primary_10_1007_s11912_021_01090_2 crossref_primary_10_1016_j_purol_2020_09_012 crossref_primary_10_1016_j_ajpath_2019_02_009 crossref_primary_10_1016_j_mce_2018_10_023 crossref_primary_10_1016_j_cll_2023_08_003 crossref_primary_10_1038_s41585_019_0178_2 crossref_primary_10_5534_wjmh_200030 crossref_primary_10_5858_arpa_2017_0410_OA crossref_primary_10_6004_jnccn_2019_0023 crossref_primary_10_1038_s41572_020_00243_0 crossref_primary_10_1016_j_euf_2020_10_007 crossref_primary_10_1111_his_13821 crossref_primary_10_1166_jbn_2023_3702 crossref_primary_10_1002_path_5652 crossref_primary_10_3390_cancers15235512 crossref_primary_10_1007_s00345_024_05369_4 crossref_primary_10_1101_cshperspect_a030601 crossref_primary_10_1016_j_urolonc_2017_12_022 crossref_primary_10_1016_j_urology_2021_05_028 crossref_primary_10_1016_j_ebiom_2023_104436 crossref_primary_10_1097_PAP_0000000000000192 crossref_primary_10_1007_s10147_020_01756_0 crossref_primary_10_1158_0008_5472_CAN_23_1176 crossref_primary_10_1186_s13073_024_01302_x crossref_primary_10_1016_j_eururo_2019_01_027 crossref_primary_10_5858_arpa_2020_0015_RA crossref_primary_10_1038_s41467_021_26489_0 crossref_primary_10_1016_j_eururo_2018_12_036 crossref_primary_10_1038_s41379_021_00860_4 crossref_primary_10_1016_j_molcel_2020_10_033 crossref_primary_10_1186_s12885_019_6032_3 crossref_primary_10_1111_his_14531 crossref_primary_10_1007_s11912_020_0863_6 crossref_primary_10_1186_s12885_021_08529_6 crossref_primary_10_1038_s41391_022_00600_y crossref_primary_10_1200_JCO_19_02768 crossref_primary_10_3390_cancers16091650 crossref_primary_10_1016_j_clgc_2023_10_005 crossref_primary_10_1186_s12885_017_3976_z crossref_primary_10_1172_jci_insight_123468 crossref_primary_10_1186_s12916_022_02430_0 crossref_primary_10_1002_bco2_367 crossref_primary_10_1111_iju_15299 crossref_primary_10_3390_cancers15082217 crossref_primary_10_3390_cancers14030820 crossref_primary_10_3390_cancers16112002 crossref_primary_10_1097_PAP_0000000000000245 crossref_primary_10_1016_j_eururo_2022_05_007 crossref_primary_10_3389_fcell_2022_707405 crossref_primary_10_3390_cancers13246243 |
| Cites_doi | 10.1038/ng.2771 10.1016/j.eururo.2016.10.013 10.1016/j.ejca.2012.02.003 10.1038/modpathol.2011.176 10.1158/0008-5472.CAN-16-0902 10.1016/j.ejca.2014.03.009 10.1016/j.eururo.2014.09.006 10.1002/pros.23005 10.1200/JCO.2003.01.075 10.1038/ng.3221 10.1126/scitranslmed.aac5671 10.1097/PAS.0000000000000465 10.1038/modpathol.2016.49 10.18632/oncotarget.2879 10.1038/ncomms13671 10.1016/j.ccr.2010.05.026 10.1038/ng.3315 10.1016/j.eururo.2016.07.008 10.1016/S1470-2045(16)30491-0 10.1016/S1470-2045(14)71021-6 10.1016/j.eururo.2013.03.033 10.1158/1078-0432.CCR-16-0381 10.1186/1471-2105-15-78 10.1016/S1470-2045(14)71113-1 10.1016/j.humpath.2016.10.013 10.1016/j.eururo.2014.05.039 10.1038/modpathol.2014.116 10.1016/S0360-3016(03)01621-3 10.1038/nature20788 10.1158/1078-0432.CCR-11-2711 10.1111/apm.12533 10.1073/pnas.1411446111 10.1016/j.eururo.2015.12.003 |
| ContentType | Journal Article |
| Copyright | 2017 European Association of Urology European Association of Urology Copyright © 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved. |
| Copyright_xml | – notice: 2017 European Association of Urology – notice: European Association of Urology – notice: Copyright © 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.eururo.2017.04.034 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1873-7560 |
| EndPage | 674 |
| ExternalDocumentID | 28511883 10_1016_j_eururo_2017_04_034 S0302283817303445 1_s2_0_S0302283817303445 |
| Genre | Multicenter Study Journal Article |
| GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 0~B 1B1 1P~ 1~. 1~5 29G 30W 34G 39C 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 8UI AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AATTM AAXKI AAXUO AAYIC AAYWO ABBQC ABBTS ABFNM ABJNI ABLJU ABMAC ABMZM ABOCM ABWCG ABWVN ABXDB ACDAQ ACIEU ACQXL ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO AEBSH AEIPS AEKER AENEX AEUPX AEVXI AEYAO AFJKZ AFPUW AFRHN AFSIO AFTJW AFXIZ AGCQF AGHFR AGUBO AGYEJ AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AXJTR BKOJK BLXMC BNPGV CAG COF CS3 CYUIP DU5 E0A EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FB. FDB FEDTE FIRID FNPLU FYGXN G-Q GBLVA HVGLF HZ~ IHE J1W KOM M41 MO0 N9A O-L O1H O9- OAUVE OK. OW. OZT P-8 P-9 P2P PC. Q38 RKO ROL RPZ SCC SDF SDG SEL SES SEW SPCBC SSH SSZ T5K UDS UJ6 UV1 X7M Z5R ZGI ZXP ~G- AACTN AFCTW AFKWA AJOXV AMFUW RIG AAIAV ABLVK ABYKQ AHPSJ AJBFU AZPMC EFLBG LCYCR ZA5 AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 7X8 ACLOT ~HD |
| ID | FETCH-LOGICAL-c536t-ad491d4904d203535346419e4c892cebf8b8aff053e812b5eaaf34b3be493d243 |
| IEDL.DBID | AIKHN |
| ISSN | 0302-2838 1873-7560 |
| IngestDate | Sun Sep 28 09:12:48 EDT 2025 Thu Apr 03 07:11:42 EDT 2025 Tue Jul 01 02:55:29 EDT 2025 Thu Apr 24 23:01:26 EDT 2025 Fri Feb 23 02:30:39 EST 2024 Sun Feb 23 10:18:59 EST 2025 Tue Aug 26 17:11:42 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | SChLAP1 Hypoxia Intraductal carcinoma Prognosis Cribriform architecture Genomic instability |
| Language | English |
| License | Copyright © 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c536t-ad491d4904d203535346419e4c892cebf8b8aff053e812b5eaaf34b3be493d243 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-1648-1473 |
| PMID | 28511883 |
| PQID | 1899793887 |
| PQPubID | 23479 |
| PageCount | 10 |
| ParticipantIDs | proquest_miscellaneous_1899793887 pubmed_primary_28511883 crossref_primary_10_1016_j_eururo_2017_04_034 crossref_citationtrail_10_1016_j_eururo_2017_04_034 elsevier_sciencedirect_doi_10_1016_j_eururo_2017_04_034 elsevier_clinicalkeyesjournals_1_s2_0_S0302283817303445 elsevier_clinicalkey_doi_10_1016_j_eururo_2017_04_034 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2017-11-01 |
| PublicationDateYYYYMMDD | 2017-11-01 |
| PublicationDate_xml | – month: 11 year: 2017 text: 2017-11-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | European urology |
| PublicationTitleAlternate | Eur Urol |
| PublicationYear | 2017 |
| Publisher | Elsevier B.V |
| Publisher_xml | – name: Elsevier B.V |
| References | Zumsteg, Spratt, Pei (bib0170) 2013; 64 Fraser, Sabelnykova, Yamaguchi (bib0235) 2017; 541 Lindberg, Kristiansen, Wiklund, Grönberg, Egevad (bib0210) 2015; 67 Prensner, Zhao, Erho (bib0260) 2014; 15 Chen, Chen, Shen (bib0275) 2015; 75 Boutros, Fraser, Harding (bib0180) 2015; 47 Lalonde, Alkallas, Chua (bib0230) 2017; 72 Milosevic, Warde, Ménard (bib0285) 2012; 18 Zhao, Chang, Spratt (bib0310) 2016; 17 Hieronymus, Schultz, Gopalan (bib0190) 2014; 111 Wei, Wang, Lampert (bib0320) 2017; 71 Taylor, Schultz, Hieronymus (bib0220) 2010; 18 Trudel, Downes, Sykes, Kron, Trachtenberg, van der Kwast (bib0200) 2014; 50 D’Amico, Moul, Carroll, Sun, Lubeck, Chen (bib0165) 2003; 21 Prensner, Iyer, Sahu (bib0255) 2013; 45 Figiel, Vasseur, Bruyere, Rozet, Maheo, Fromont (bib0290) 2017; 61 Cooperberg, Davicioni, Crisan, Jenkins, Ghadessi, Karnes (bib0305) 2015; 67 Hoogland, Jenster, van Weerden (bib0225) 2012; 25 Chua, Bristow (bib0295) 2016; 22 Lalonde, Ishkanian, Sykes (bib0185) 2014; 15 Egevad, Delahunt, Srigley, Samaratunga (bib0250) 2016; 124 Cooper, Eeles, Wedge (bib0175) 2015; 47 Khani, Epstein (bib0270) 2015; 39 Kweldam, Wildhagen, Steyerberg, Bangma, van der Kwast, van Leenders (bib0205) 2015; 28 You, Knudsen, Erho (bib0315) 2016; 76 Van der Kwast, Al Daoud, Collette (bib0195) 2012; 48 Böttcher, Hoogland, Dits (bib0325) 2015; 6 Tarish, Schultz, Tanoglidi (bib0300) 2015; 7 Taylor, Fraser, Livingstone (bib0215) 2017; 8 Govind, Zia, Hennings-Yeomans (bib0240) 2014; 15 Kweldam, Kümmerlin, Nieboer (bib0280) 2016; 29 Parker, Milosevic, Toi (bib0245) 2004; 58 Mehra, Udager, Ahearn (bib0265) 2016; 70 Parker (10.1016/j.eururo.2017.04.034_bib0245) 2004; 58 Figiel (10.1016/j.eururo.2017.04.034_bib0290) 2017; 61 Hoogland (10.1016/j.eururo.2017.04.034_bib0225) 2012; 25 Chen (10.1016/j.eururo.2017.04.034_bib0275) 2015; 75 Taylor (10.1016/j.eururo.2017.04.034_bib0215) 2017; 8 Lindberg (10.1016/j.eururo.2017.04.034_bib0210) 2015; 67 Taylor (10.1016/j.eururo.2017.04.034_bib0220) 2010; 18 Fraser (10.1016/j.eururo.2017.04.034_bib0235) 2017; 541 Milosevic (10.1016/j.eururo.2017.04.034_bib0285) 2012; 18 Lalonde (10.1016/j.eururo.2017.04.034_bib0185) 2014; 15 Chua (10.1016/j.eururo.2017.04.034_bib0295) 2016; 22 Böttcher (10.1016/j.eururo.2017.04.034_bib0325) 2015; 6 Zhao (10.1016/j.eururo.2017.04.034_bib0310) 2016; 17 Trudel (10.1016/j.eururo.2017.04.034_bib0200) 2014; 50 D’Amico (10.1016/j.eururo.2017.04.034_bib0165) 2003; 21 Khani (10.1016/j.eururo.2017.04.034_bib0270) 2015; 39 Kweldam (10.1016/j.eururo.2017.04.034_bib0280) 2016; 29 You (10.1016/j.eururo.2017.04.034_bib0315) 2016; 76 Zumsteg (10.1016/j.eururo.2017.04.034_bib0170) 2013; 64 Tarish (10.1016/j.eururo.2017.04.034_bib0300) 2015; 7 Prensner (10.1016/j.eururo.2017.04.034_bib0260) 2014; 15 Boutros (10.1016/j.eururo.2017.04.034_bib0180) 2015; 47 Van der Kwast (10.1016/j.eururo.2017.04.034_bib0195) 2012; 48 Govind (10.1016/j.eururo.2017.04.034_bib0240) 2014; 15 Prensner (10.1016/j.eururo.2017.04.034_bib0255) 2013; 45 Egevad (10.1016/j.eururo.2017.04.034_bib0250) 2016; 124 Lalonde (10.1016/j.eururo.2017.04.034_bib0230) 2017; 72 Cooper (10.1016/j.eururo.2017.04.034_bib0175) 2015; 47 Hieronymus (10.1016/j.eururo.2017.04.034_bib0190) 2014; 111 Wei (10.1016/j.eururo.2017.04.034_bib0320) 2017; 71 Kweldam (10.1016/j.eururo.2017.04.034_bib0205) 2015; 28 Cooperberg (10.1016/j.eururo.2017.04.034_bib0305) 2015; 67 Mehra (10.1016/j.eururo.2017.04.034_bib0265) 2016; 70 |
| References_xml | – volume: 45 start-page: 1392 year: 2013 end-page: 1398 ident: bib0255 article-title: The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex publication-title: Nat Genet – volume: 29 start-page: 630 year: 2016 end-page: 636 ident: bib0280 article-title: Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy publication-title: Mod Pathol – volume: 76 start-page: 4948 year: 2016 end-page: 4958 ident: bib0315 article-title: Integrated classification of prostate cancer reveals a novel luminal subtype with poor outcome publication-title: Cancer Res – volume: 67 start-page: 326 year: 2015 end-page: 333 ident: bib0305 article-title: Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort publication-title: Eur Urol – volume: 18 start-page: 2108 year: 2012 end-page: 2114 ident: bib0285 article-title: Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer publication-title: Clin Cancer Res – volume: 21 start-page: 2163 year: 2003 end-page: 2172 ident: bib0165 article-title: Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the PSA era publication-title: J Clin Oncol – volume: 8 start-page: 13671 year: 2017 ident: bib0215 article-title: Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories publication-title: Nat Commun – volume: 50 start-page: 1610 year: 2014 end-page: 1616 ident: bib0200 article-title: Prognostic impact of intraductal carcinoma and large cribriform carcinoma architecture after prostatectomy in a contemporary cohort publication-title: Eur J Cancer – volume: 47 start-page: 367 year: 2015 end-page: 372 ident: bib0175 article-title: Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue publication-title: Nat Genet – volume: 48 start-page: 1318 year: 2012 end-page: 1325 ident: bib0195 article-title: Biopsy diagnosis of intraductal carcinoma is prognostic in intermediate and high risk prostate cancer patients treated by radiotherapy publication-title: Eur J Cancer – volume: 15 start-page: 78 year: 2014 ident: bib0240 article-title: ShatterProof: operational detection and quantification of chromothripsis publication-title: BMC Bioinformatics – volume: 72 start-page: 22 year: 2017 end-page: 31 ident: bib0230 article-title: Translating a prognostic DNA genomic classifier into the clinic: retrospective validation in 563 localized prostate tumors publication-title: Eur Urol – volume: 61 start-page: 26 year: 2017 end-page: 32 ident: bib0290 article-title: Clinical significance of epithelial-mesenchymal transition (EMT) markers in prostate cancer publication-title: Hum Pathol – volume: 28 start-page: 457 year: 2015 end-page: 464 ident: bib0205 article-title: Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer publication-title: Mod Pathol – volume: 7 start-page: 312re11 year: 2015 ident: bib0300 article-title: Castration radiosensitizes prostate cancer tissue by impairing DNA double-strand break repair publication-title: Sci Transl Med – volume: 67 start-page: 819 year: 2015 end-page: 822 ident: bib0210 article-title: Tracking the origin of metastatic prostate cancer publication-title: Eur Urol – volume: 18 start-page: 11 year: 2010 end-page: 22 ident: bib0220 article-title: Integrative genomic profiling of human prostate cancer publication-title: Cancer Cell – volume: 541 start-page: 359 year: 2017 end-page: 364 ident: bib0235 article-title: Genomic hallmarks of localized, non-indolent prostate cancer publication-title: Nature – volume: 6 start-page: 4036 year: 2015 end-page: 4050 ident: bib0325 article-title: Novel long non-coding RNAs are specific diagnostic and prognostic markers for prostate cancer publication-title: Oncotarget – volume: 39 start-page: 1383 year: 2015 end-page: 1389 ident: bib0270 article-title: Prostate biopsy specimens with Gleason 3 publication-title: Am J Surg Pathol – volume: 64 start-page: 895 year: 2013 end-page: 902 ident: bib0170 article-title: A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy publication-title: Eur Urol – volume: 47 start-page: 736 year: 2015 end-page: 745 ident: bib0180 article-title: Spatial genomic heterogeneity within localized, multifocal prostate cancer publication-title: Nat Genet – volume: 22 start-page: 3124 year: 2016 end-page: 3126 ident: bib0295 article-title: Testosterone in androgen receptor signaling and DNA repair: enemy or frenemy? publication-title: Clin Cancer Res – volume: 17 start-page: 1612 year: 2016 end-page: 1620 ident: bib0310 article-title: Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis publication-title: Lancet Oncol – volume: 71 start-page: 183 year: 2017 end-page: 192 ident: bib0320 article-title: Intratumoral and intertumoral genomic heterogeneity of multifocal localized prostate cancer impacts molecular classifications and genomic prognosticators publication-title: Eur Urol – volume: 15 start-page: 1469 year: 2014 end-page: 1480 ident: bib0260 article-title: RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1 publication-title: Lancet Oncol – volume: 70 start-page: 549 year: 2016 end-page: 552 ident: bib0265 article-title: Overexpression of the long non-coding RNA SChLAP1 independently predicts lethal prostate cancer publication-title: Eur Urol – volume: 111 start-page: 11139 year: 2014 end-page: 11144 ident: bib0190 article-title: Copy number alteration burden predicts prostate cancer relapse publication-title: Proc Natl Acad Sci U S A – volume: 25 start-page: 471 year: 2012 end-page: 479 ident: bib0225 article-title: ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer publication-title: Mod Pathol – volume: 58 start-page: 750 year: 2004 end-page: 757 ident: bib0245 article-title: Polarographic electrode study of tumor oxygenation in clinically localized prostate cancer publication-title: Int J Radiat Oncol Biol Phys – volume: 124 start-page: 433 year: 2016 end-page: 435 ident: bib0250 article-title: International Society of Urological Pathology (ISUP) grading of prostate cancer—an ISUP consensus on contemporary grading publication-title: APMIS – volume: 75 start-page: 1247 year: 2015 end-page: 1254 ident: bib0275 article-title: The presence and clinical implication of intraductal carcinoma of prostate in metastatic castration resistant prostate cancer publication-title: Prostate – volume: 15 start-page: 1521 year: 2014 end-page: 1532 ident: bib0185 article-title: Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study publication-title: Lancet Oncol – volume: 45 start-page: 1392 year: 2013 ident: 10.1016/j.eururo.2017.04.034_bib0255 article-title: The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex publication-title: Nat Genet doi: 10.1038/ng.2771 – volume: 72 start-page: 22 year: 2017 ident: 10.1016/j.eururo.2017.04.034_bib0230 article-title: Translating a prognostic DNA genomic classifier into the clinic: retrospective validation in 563 localized prostate tumors publication-title: Eur Urol doi: 10.1016/j.eururo.2016.10.013 – volume: 48 start-page: 1318 year: 2012 ident: 10.1016/j.eururo.2017.04.034_bib0195 article-title: Biopsy diagnosis of intraductal carcinoma is prognostic in intermediate and high risk prostate cancer patients treated by radiotherapy publication-title: Eur J Cancer doi: 10.1016/j.ejca.2012.02.003 – volume: 25 start-page: 471 year: 2012 ident: 10.1016/j.eururo.2017.04.034_bib0225 article-title: ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer publication-title: Mod Pathol doi: 10.1038/modpathol.2011.176 – volume: 76 start-page: 4948 year: 2016 ident: 10.1016/j.eururo.2017.04.034_bib0315 article-title: Integrated classification of prostate cancer reveals a novel luminal subtype with poor outcome publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-16-0902 – volume: 50 start-page: 1610 year: 2014 ident: 10.1016/j.eururo.2017.04.034_bib0200 article-title: Prognostic impact of intraductal carcinoma and large cribriform carcinoma architecture after prostatectomy in a contemporary cohort publication-title: Eur J Cancer doi: 10.1016/j.ejca.2014.03.009 – volume: 67 start-page: 819 year: 2015 ident: 10.1016/j.eururo.2017.04.034_bib0210 article-title: Tracking the origin of metastatic prostate cancer publication-title: Eur Urol doi: 10.1016/j.eururo.2014.09.006 – volume: 75 start-page: 1247 year: 2015 ident: 10.1016/j.eururo.2017.04.034_bib0275 article-title: The presence and clinical implication of intraductal carcinoma of prostate in metastatic castration resistant prostate cancer publication-title: Prostate doi: 10.1002/pros.23005 – volume: 21 start-page: 2163 year: 2003 ident: 10.1016/j.eururo.2017.04.034_bib0165 article-title: Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the PSA era publication-title: J Clin Oncol doi: 10.1200/JCO.2003.01.075 – volume: 47 start-page: 367 year: 2015 ident: 10.1016/j.eururo.2017.04.034_bib0175 article-title: Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue publication-title: Nat Genet doi: 10.1038/ng.3221 – volume: 7 start-page: 312re11 year: 2015 ident: 10.1016/j.eururo.2017.04.034_bib0300 article-title: Castration radiosensitizes prostate cancer tissue by impairing DNA double-strand break repair publication-title: Sci Transl Med doi: 10.1126/scitranslmed.aac5671 – volume: 39 start-page: 1383 year: 2015 ident: 10.1016/j.eururo.2017.04.034_bib0270 article-title: Prostate biopsy specimens with Gleason 3+3=6 and intraductal carcinoma: radical prostatectomy findings and clinical outcomes publication-title: Am J Surg Pathol doi: 10.1097/PAS.0000000000000465 – volume: 29 start-page: 630 year: 2016 ident: 10.1016/j.eururo.2017.04.034_bib0280 article-title: Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy publication-title: Mod Pathol doi: 10.1038/modpathol.2016.49 – volume: 6 start-page: 4036 year: 2015 ident: 10.1016/j.eururo.2017.04.034_bib0325 article-title: Novel long non-coding RNAs are specific diagnostic and prognostic markers for prostate cancer publication-title: Oncotarget doi: 10.18632/oncotarget.2879 – volume: 8 start-page: 13671 year: 2017 ident: 10.1016/j.eururo.2017.04.034_bib0215 article-title: Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories publication-title: Nat Commun doi: 10.1038/ncomms13671 – volume: 18 start-page: 11 year: 2010 ident: 10.1016/j.eururo.2017.04.034_bib0220 article-title: Integrative genomic profiling of human prostate cancer publication-title: Cancer Cell doi: 10.1016/j.ccr.2010.05.026 – volume: 47 start-page: 736 year: 2015 ident: 10.1016/j.eururo.2017.04.034_bib0180 article-title: Spatial genomic heterogeneity within localized, multifocal prostate cancer publication-title: Nat Genet doi: 10.1038/ng.3315 – volume: 71 start-page: 183 year: 2017 ident: 10.1016/j.eururo.2017.04.034_bib0320 article-title: Intratumoral and intertumoral genomic heterogeneity of multifocal localized prostate cancer impacts molecular classifications and genomic prognosticators publication-title: Eur Urol doi: 10.1016/j.eururo.2016.07.008 – volume: 17 start-page: 1612 year: 2016 ident: 10.1016/j.eururo.2017.04.034_bib0310 article-title: Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis publication-title: Lancet Oncol doi: 10.1016/S1470-2045(16)30491-0 – volume: 15 start-page: 1521 year: 2014 ident: 10.1016/j.eururo.2017.04.034_bib0185 article-title: Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)71021-6 – volume: 64 start-page: 895 year: 2013 ident: 10.1016/j.eururo.2017.04.034_bib0170 article-title: A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy publication-title: Eur Urol doi: 10.1016/j.eururo.2013.03.033 – volume: 22 start-page: 3124 year: 2016 ident: 10.1016/j.eururo.2017.04.034_bib0295 article-title: Testosterone in androgen receptor signaling and DNA repair: enemy or frenemy? publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-16-0381 – volume: 15 start-page: 78 year: 2014 ident: 10.1016/j.eururo.2017.04.034_bib0240 article-title: ShatterProof: operational detection and quantification of chromothripsis publication-title: BMC Bioinformatics doi: 10.1186/1471-2105-15-78 – volume: 15 start-page: 1469 year: 2014 ident: 10.1016/j.eururo.2017.04.034_bib0260 article-title: RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)71113-1 – volume: 61 start-page: 26 year: 2017 ident: 10.1016/j.eururo.2017.04.034_bib0290 article-title: Clinical significance of epithelial-mesenchymal transition (EMT) markers in prostate cancer publication-title: Hum Pathol doi: 10.1016/j.humpath.2016.10.013 – volume: 67 start-page: 326 year: 2015 ident: 10.1016/j.eururo.2017.04.034_bib0305 article-title: Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort publication-title: Eur Urol doi: 10.1016/j.eururo.2014.05.039 – volume: 28 start-page: 457 year: 2015 ident: 10.1016/j.eururo.2017.04.034_bib0205 article-title: Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer publication-title: Mod Pathol doi: 10.1038/modpathol.2014.116 – volume: 58 start-page: 750 year: 2004 ident: 10.1016/j.eururo.2017.04.034_bib0245 article-title: Polarographic electrode study of tumor oxygenation in clinically localized prostate cancer publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/S0360-3016(03)01621-3 – volume: 541 start-page: 359 year: 2017 ident: 10.1016/j.eururo.2017.04.034_bib0235 article-title: Genomic hallmarks of localized, non-indolent prostate cancer publication-title: Nature doi: 10.1038/nature20788 – volume: 18 start-page: 2108 year: 2012 ident: 10.1016/j.eururo.2017.04.034_bib0285 article-title: Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-11-2711 – volume: 124 start-page: 433 year: 2016 ident: 10.1016/j.eururo.2017.04.034_bib0250 article-title: International Society of Urological Pathology (ISUP) grading of prostate cancer—an ISUP consensus on contemporary grading publication-title: APMIS doi: 10.1111/apm.12533 – volume: 111 start-page: 11139 year: 2014 ident: 10.1016/j.eururo.2017.04.034_bib0190 article-title: Copy number alteration burden predicts prostate cancer relapse publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1411446111 – volume: 70 start-page: 549 year: 2016 ident: 10.1016/j.eururo.2017.04.034_bib0265 article-title: Overexpression of the long non-coding RNA SChLAP1 independently predicts lethal prostate cancer publication-title: Eur Urol doi: 10.1016/j.eururo.2015.12.003 |
| SSID | ssj0003593 |
| Score | 2.5812676 |
| Snippet | Intraductal carcinoma (IDC) and cribriform architecture (CA) represent unfavorable subpathologies in localized prostate cancer. We recently showed that IDC... Abstract Background Intraductal carcinoma (IDC) and cribriform architecture (CA) represent unfavorable subpathologies in localized prostate cancer. We recently... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 665 |
| SubjectTerms | Adenocarcinoma - genetics Adenocarcinoma - mortality Adenocarcinoma - pathology Adenocarcinoma - therapy Biomarkers, Tumor - genetics Cribriform architecture Disease Progression Disease-Free Survival Gene Expression Regulation, Neoplastic Genetic Predisposition to Disease Genomic Instability Humans Hypoxia Intraductal carcinoma Kaplan-Meier Estimate Male Neoplasm Invasiveness Netherlands New York City Ontario Phenotype Prognosis Proportional Hazards Models Prostatic Neoplasms - genetics Prostatic Neoplasms - mortality Prostatic Neoplasms - pathology Prostatic Neoplasms - therapy Quebec Risk Factors RNA, Long Noncoding - genetics SChLAP1 Time Factors Transcriptome Treatment Outcome Tumor Hypoxia Urology |
| Title | A Prostate Cancer “Nimbosus”: Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0302283817303445 https://www.clinicalkey.es/playcontent/1-s2.0-S0302283817303445 https://dx.doi.org/10.1016/j.eururo.2017.04.034 https://www.ncbi.nlm.nih.gov/pubmed/28511883 https://www.proquest.com/docview/1899793887 |
| Volume | 72 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbpwwELaSjVT1UvW_25_IlXqlC9iA6Q3RptufrCKlkXKzbLC3G6XsCpZDLlUeoQ-QvFyepDNgVq3aKFWFOIAY2XjGMx9ivhlCXlk_DkObll4R8cQDBJ54yirlqaQ0Fj6IYu4jG3l_Fk-P-Mfj6HiL5AMXBtMqne_vfXrnrd2diVvNyWqxmByCeWLtFhGAkTLOo22yE0K0FyOyk334NJ1tHDJztXdZx0RmYmDQdWlepq3bGlmAQdLVPGX8ugh1HQLtItHeXXLHQUia9bO8R7ZMdZ_c2nc_yR-QHxk9QC4HoEiao1JrenV-MVt808umba7OL9_Q96ZjI1NMFegLdZ9RVZX0MP_6OTsI6NszmNfcdfaiXW-k1aKi2Xzep81WdGlBeF0rLBcLk0HhvEb6AIJgCu4IWx13jtU0D8nR3rsv-dRzjRdAYyxee6rkaQCnz8sQVg8OHvMgNbwQaVgYbYUWylrYvwbwgY6MUpZxzbThKStDzh6RUbWszBNCAV3EJong-QQr01iRpFjkzxgT6EKnekzYsNiycFXJsTnGqRzSz05kryKJKpI-l6CiMfE2Uqu-KscNz0eDHuXAOAUfKSFs3CCX_E3ONG6jNzKQTSh9-Ycx_ir5mz3_w5gvB0OTsNXx_42qzLKFseDbGNwphIUxedxb4ObtQ0TOQrCn_z3uM3Ibr3qe5XMyWteteQGAa613yfbr78Gu21Y_AeWALd0 |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LbtswECVSB2i7KfqP-2WBbgVLIvXLTlCbOo1tBEgCZEeQEuk6SGRDshbZ5Qg9QHq5nKQzEmW0aIMUheGNrQEpznD4BM17Q8hH44a-b5LCyQMeOYDAI0caKR0ZFdrAA1HIXWQjT2fh-IR_PQ1Ot0jWc2GwrNLm_i6nt9na_jKyqzlaLRajIwhP1G6JPQhSxnlwj2xzbGo9INvp_sF4tknIzGrvspaJzOKeQdeWeemmaipkAXpRq3nK-G0n1G0ItD2J9h6TRxZC0rSb5ROypcun5P7UviR_Rr6n9BC5HIAiaYZOrejN1fVscaGWdVPfXP3YpV90y0amWCrQCXVfUlkW9Cj7NkkPPfrpEuY1t529aNsbabUoaTqfd2WzJV0aMF5XEuViYTJonFVIH0AQTCEdYavjNrHq-jk52ft8nI0d23gBPMbCtSMLnnjwdXnhw-rBh4fcSzTP48TPtTKxiqUxsH814AMVaCkN44opzRNW-Jy9IINyWeodQgFdhDoK4PoIlWlMHCUo8qe19lSuEjUkrF9skVtVcmyOcS768rMz0blIoIuEywW4aEicjdWqU-W44_qg96PoGaeQIwUcG3fYRX-z07Xd6LXwRO0LV_wRjL9a_hbP_zDmhz7QBGx1fH8jS71sYCx4NoZ0CsfCkLzsInBz9z4i5zhmr_573Pfkwfh4OhGT_dnBa_IQ_-k4l2_IYF01-i2Ar7V6ZzfXT_1TL8M |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+Prostate+Cancer+%22Nimbosus%22%3A+Genomic+Instability+and+SChLAP1+Dysregulation+Underpin+Aggression+of+Intraductal+and+Cribriform+Subpathologies&rft.jtitle=European+urology&rft.au=Chua%2C+Melvin+L+K&rft.au=Lo%2C+Winnie&rft.au=Pintilie%2C+Melania&rft.au=Murgic%2C+Jure&rft.date=2017-11-01&rft.issn=1873-7560&rft.eissn=1873-7560&rft.volume=72&rft.issue=5&rft.spage=665&rft_id=info:doi/10.1016%2Fj.eururo.2017.04.034&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0302-2838&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0302-2838&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0302-2838&client=summon |